Biomarin Pharmaceutical market cap BMRN
Share price times shares outstanding: what the whole company sells for, since 2010.
- Today, Nov 2, 2026
- $11.1B
- Highest close in our data
- $23.9B
- Jul 2015
Biomarin Pharmaceutical is worth $11.1B at the close on Nov 2, 2026, at $57.44 a share.
That is up 12% over the last year and down 28% over five years.
Its highest close in our data was $23.9B in Jul 2015.
Market cap over time
Year by year
| Year | End of year | Low | High | Change |
|---|---|---|---|---|
| 2026 so far | $11.1B | $10B | $13B | −3% |
| 2025 | $11.5B | $9.9B | $13.8B | −10% |
| 2024 | $12.7B | $12.1B | $18.2B | −30% |
| 2023 | $18.2B | $15B | $21.8B | −6% |
| 2022 | $19.2B | $13.9B | $20.2B | +19% |
| 2021 | $16.2B | $13.5B | $16.8B | +2% |
| 2020 | $15.9B | $13.1B | $23.2B | +4% |
| 2019 | $15.4B | $11.8B | $17.6B | +3% |
| 2018 | $14.9B | $13.4B | $18.3B | −5% |
| 2017 | $15.7B | $14.2B | $16.7B | +10% |
| 2016 | $14.2B | $11B | $16.1B | −16% |
| 2015 | $16.9B | $13.6B | $23.9B | +25% |
| 2014 | $13.5B | $8.2B | $13.8B | +37% |
| 2013 | $9.8B | $6.4B | $10.8B | +66% |
| 2012 | $5.9B | $3.8B | $6.1B | +51% |
| 2011 | $3.9B | $2.6B | $4B | +42% |
| 2010 | $2.8B | $2.1B | $2.9B | n/a |
Against its peers
Companies in Drug Manufacturers - General nearest Biomarin Pharmaceutical's size, closest first, today.
| Company | Market cap |
|---|---|
| BMRNBiomarin Pharmaceutical | $11.1B |
| TGTXTG Therapeutics | $9.2B |
| PTGXProtagonist Therapeutics | $9B |
| JAZZJazz Pharmaceuticals | $13.9B |
| CORTCorcept Therapeutics | $8.7B |
| ALKSAlkermes plc. | $7.5B |
| KNSAKiniksa Pharmaceuticals International | $7.1B |
| AMRXAmneal Pharmaceuticals | $6.5B |
| LGNDLigand Pharmaceuticals | $6.1B |
| INDVIndivior Pharmaceuticals | $4.3B |
| ARQTArcutis Biotherapeutics | $3.9B |
| Peer median | $7.3B |
What the market cap tells you
Share price times shares outstanding: what the whole company sells for today.
Size, not quality. Large caps move slower and are covered more. That is all it tells you.
More on Biomarin Pharmaceutical
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.